<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8344">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02052804</url>
  </required_header>
  <id_info>
    <org_study_id>AHFMRITG200801018</org_study_id>
    <nct_id>NCT02052804</nct_id>
  </id_info>
  <brief_title>Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics</brief_title>
  <acronym>Alberta HEART</acronym>
  <official_title>Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <authority>Canada: University of Alberta HREB (Biomedical Panel)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are: 1) to design new diagnostic criteria used to accurately
      define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk
      factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular
      mechanisms involved with the development and progression of HFpEF; 4) to design and test new
      therapeutic strategies for patients with HFpEF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percent of patients meeting new diagnostic criteria for HFpEF</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of Alberta, Canada with heart failure or at risk for developing heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 No clinically overt heart failure

          -  Group 2 Known coronary artery disease

          -  Group 3 Known heart failure with preserved ejection fraction

          -  Group 4 Known heart failure with reduced ejection fraction

          -  Group 5 Healthy age-matched controls

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Known malignancy with expected survival &lt;1 year

          -  Pregnant or recent pregnancy &lt;6 months

          -  Recent event (&lt;2 weeks since Acute Coronary Syndrome, Heart failure or other
             admission

          -  Severe mitral or aortic stenosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Dyck, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marleen Irwin, RRT(C), FHRS, CCDS</last_name>
    <phone>(780) 492-9753</phone>
    <email>mirwin@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darlene Ramadan, RN, BN</last_name>
    <phone>(403) 210-7356</phone>
    <email>ramadan@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Ramadan, RN, BN</last_name>
      <phone>(403) 210-7356</phone>
      <email>ramadan@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Jackson-Carter, RN, BN</last_name>
      <phone>(403) 220-8709</phone>
      <email>jacksola@ucalgary.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Todd Anderson, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Irwin, RRT(C), FHRS, CCDS</last_name>
      <phone>(780) 492-2906</phone>
      <email>mirwin@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Justin Ezekowitz, MBBCh, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Justin Ezekowitz</investigator_full_name>
    <investigator_title>Associate Professor, University of Alberta; Director, Heart Function Clinic- Mazankowski Alberta Heart Institute</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
